Bora Appoints Industry Veteran as Chief Commercial Officer
TAIPEI, TAIWAN, May 13, 2025 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, today announced the appointment of Jean-Baptiste (“JB”) Agnus as Chief Commercial Officer. In this role, he will lead Bora’s commercial strategy for its sterile injectables and complex small molecule offerings, as well as playing a key role in its M&A and strategic partnership initiatives.
“I am thrilled to welcome JB, who brings more than 25 years of biopharmaceutical industry experience. I look forward to working with him to meet the needs of our partners and the patients we serve together, and support this rapidly growing organization,” commented J.D. Mowery, President of Bora’s CDMO Division. “We at Bora are deeply committed to providing the highest standards of quality and customer service. JB’s experience and leadership will serve us well as we implement growth and investment strategies to better serve our clients and patients worldwide.”
Agnus joins Bora Group from KBI Biopharma, where he led global business development. Prior to that, he held various senior leadership roles in business development at AGC Biologics, Ajinomoto Bio-Pharma Services, Novasep, and Isochem. He holds a bachelor’s degree in organic chemistry from Université Paul Sabatier Toulouse III, Toulouse, France, and a master’s degree in chemical engineering from Centrale Méditerranée, Marseille, France.
[ends]
About Bora Pharmaceuticals
Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharmaceutical products. From our world-class sites in North America and Asia, we deliver drug products with unparalleled quality to more than 100 markets around the world. For more information, visit https://boracdmo.com.
